Global Inhaled Corticosteroids Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Inhaled Corticosteroids Market Size

• The global inhaled corticosteroids market size was valued at USD 2.72 billion in 2025 and is expected to reach USD 3.95 billion by 2033, at a CAGR of 4.80% during the forecast period
• The market growth is largely fueled by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), along with growing awareness regarding effective long-term disease management, leading to increased adoption of inhaled corticosteroids in both hospital and homecare settings
• Furthermore, rising demand for targeted and efficient drug delivery systems, along with advancements in inhalation devices and combination therapies, is establishing inhaled corticosteroids as a cornerstone of respiratory treatment. These converging factors are accelerating the uptake of Inhaled Corticosteroids solutions, thereby significantly boosting the industry's growth

Inhaled Corticosteroids Market Analysis

• Inhaled corticosteroids, offering targeted anti-inflammatory treatment for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), are increasingly vital components of modern respiratory care due to their effectiveness in reducing airway inflammation and improving long-term disease control in both clinical and homecare settings
• The escalating demand for inhaled corticosteroids is primarily fueled by the rising prevalence of respiratory disorders, increasing air pollution levels, and growing awareness regarding early and effective disease management among patients and healthcare providers
• North America dominated the inhaled corticosteroids market with the largest revenue share of 36.8% in 2025, driven by high prevalence of asthma and COPD, advanced healthcare infrastructure, strong presence of pharmaceutical companies, and widespread adoption of combination inhaler therapies in the U.S.
• Asia-Pacific is expected to be the fastest growing region in the inhaled corticosteroids market during the forecast period due to rising pollution levels, increasing patient population, improving healthcare access, and growing awareness regarding respiratory disease treatment
• The asthma segment dominated the largest market revenue share of 54.7% in 2025, driven by the rising global prevalence of asthma and strong clinical recommendations supporting inhaled corticosteroids as first-line therapy

Report Scope and Inhaled Corticosteroids Market Segmentation      

Inhaled Corticosteroids Market Trends

“Advancements in Inhaler Technologies and Combination Therapies”

• A significant and accelerating trend in the global Inhaled Corticosteroids market is the advancement of inhaler technologies and the increasing adoption of combination therapies for respiratory disease management
• For instance, the development of combination inhalers that include corticosteroids along with long-acting beta-agonists (LABAs) is improving treatment efficacy for conditions such as asthma and chronic obstructive pulmonary disease (COPD)
• Innovations in inhaler devices, including dry powder inhalers (DPIs) and metered-dose inhalers (MDIs), are enhancing drug delivery efficiency and patient adherence.
• In addition, the introduction of smart inhalers with dose tracking and adherence monitoring features is supporting better disease management and improving clinical outcomes
• The growing focus on patient-centric treatment approaches and ease of use is further driving the adoption of advanced inhalation therapies
• This trend toward more effective, user-friendly, and combination-based therapies is transforming respiratory care and improving long-term disease control

Inhaled Corticosteroids Market Dynamics

Driver

“Rising Prevalence of Respiratory Diseases and Increasing Demand for Effective Treatment”

• The increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) is a major driver for the growth of the Inhaled Corticosteroids market
• The growing burden of air pollution, smoking habits, and occupational respiratory risks is significantly contributing to the rise in these chronic conditions
• For instance, the increasing number of asthma patients globally has led to a higher demand for inhaled corticosteroids as a first-line anti-inflammatory treatment
• In addition, growing awareness regarding early diagnosis and long-term disease management is encouraging the use of maintenance therapies such as inhaled corticosteroids
• Improvements in healthcare access and the availability of advanced inhalation devices are further supporting market growth across both developed and developing regions
• The increasing aging population, which is more prone to chronic respiratory disorders, is expected to further drive demand for inhaled corticosteroid therapies

Restraint/Challenge

“Side Effects, High Treatment Costs, and Patient Compliance Issues”

• The potential side effects associated with long-term use of inhaled corticosteroids, such as oral thrush, hoarseness, and reduced bone density, remain a key concern for patients and healthcare providers
• For instance, prolonged use of high-dose inhaled corticosteroids in some patients has been associated with local and systemic side effects, leading to hesitation in long-term adherence to therapy. In addition, the cost of combination inhalers and advanced drug delivery systems can be relatively high, limiting access for patients in low- and middle-income regions
• Patient non-adherence due to improper inhaler technique or lack of awareness also poses a significant challenge to effective treatment outcomes
• Variability in drug response among patients and the need for personalized treatment approaches further complicate disease management
• Regulatory challenges and the need for continuous product innovation also add to the complexity for market players
• Addressing these challenges through patient education, cost-effective treatment options, and improved inhaler designs will be crucial for sustained market growth

Inhaled Corticosteroids Market Scope

The market is segmented on the basis of indication, type, dosage form, end-users, and distribution channel.

• By Indication

On the basis of indication, the Inhaled Corticosteroids market is segmented into asthma, chronic obstructive pulmonary disease (COPD), and others. The asthma segment dominated the largest market revenue share of 54.7% in 2025, driven by the rising global prevalence of asthma and strong clinical recommendations supporting inhaled corticosteroids as first-line therapy. Increasing environmental pollution, urbanization, and allergen exposure have significantly contributed to the growing patient pool. The segment benefits from continuous advancements in inhalation therapies, including combination inhalers that improve adherence and outcomes. Pediatric and elderly populations, who are more susceptible to asthma, further strengthen demand. Government screening initiatives and awareness campaigns are also encouraging early diagnosis and treatment adoption. In addition, improved healthcare infrastructure and accessibility to inhalers are boosting segment growth. Pharmaceutical companies are actively focusing on developing advanced formulations with reduced side effects. The availability of cost-effective generics is further expanding access in emerging markets. Moreover, long-term disease management requirements ensure consistent demand for inhaled corticosteroids in asthma care.

The COPD segment is expected to witness the fastest CAGR of 8.9% from 2026 to 2033, driven by the increasing prevalence of chronic respiratory disorders among aging populations. Rising smoking rates and prolonged exposure to air pollutants are major contributing factors to COPD incidence. The growing adoption of combination therapies involving corticosteroids and bronchodilators is enhancing treatment effectiveness. Increased awareness regarding early diagnosis and disease management is also supporting growth. Healthcare systems are focusing more on reducing COPD-related hospitalizations, further boosting demand. Technological advancements in inhaler devices are improving drug delivery efficiency and patient compliance. Expanding access to healthcare services in developing regions is also contributing to segment expansion. In addition, pharmaceutical companies are investing in innovative therapies targeting severe COPD cases. The shift toward personalized treatment approaches is further accelerating adoption. Overall, the segment is expected to witness strong growth due to rising disease burden and improved treatment options.

• By Type

On the basis of type, the market is segmented into beclomethasone dipropionate, budesonide, fluticasone, mometasone, and others. The fluticasone segment dominated the market with a revenue share of 31.6% in 2025, owing to its high efficacy and widespread clinical use in managing both asthma and COPD. It offers strong anti-inflammatory properties and a favorable safety profile, making it a preferred choice among healthcare professionals. The increasing availability of combination inhalers containing fluticasone is further boosting its adoption. Strong brand presence and physician preference are also key factors supporting its dominance. The segment benefits from ongoing research and development aimed at improving drug formulations. In addition, patient preference for effective long-term maintenance therapies is driving demand. The rising number of respiratory disorder cases globally is further strengthening segment growth. Improved access to healthcare services and medications is also contributing to expansion. Moreover, pharmaceutical companies are focusing on expanding their product portfolios, enhancing market penetration.

The budesonide segment is projected to grow at the fastest CAGR of 9.4% from 2026 to 2033, driven by its increasing use across diverse patient populations. Budesonide is widely preferred due to its lower systemic side effects and suitability for both adults and children. The growing demand for safer and effective inhalation therapies is supporting segment growth. Increasing adoption in emerging markets and the availability of generic versions are enhancing affordability. Continuous product innovation and development of combination therapies are further boosting demand. The segment is also benefiting from rising awareness regarding respiratory disease management. Improved healthcare access and diagnostic capabilities are supporting early treatment initiation. In addition, pharmaceutical companies are investing in expanding distribution networks. The rising focus on preventive healthcare is also contributing to growth. Overall, the segment is expected to witness rapid expansion during the forecast period.

• By Dosage Form

On the basis of dosage form, the market is segmented into aerosol liquid, aerosol powder, powder, and suspension. The aerosol powder segment dominated the market with a share of 42.3% in 2025, primarily due to its ease of use and high patient compliance. Dry powder inhalers are widely preferred as they eliminate the need for coordination during inhalation. The segment benefits from advancements in inhaler technology that improve dose accuracy and delivery efficiency. Increasing adoption among elderly patients and children is also supporting growth. In addition, the convenience and portability of these devices make them highly attractive for long-term use. Pharmaceutical companies are focusing on developing innovative inhaler designs to enhance user experience. The rising prevalence of respiratory diseases is further driving demand for effective delivery systems. Improved accessibility and affordability of inhalers are also contributing to segment expansion. Moreover, strong clinical outcomes associated with dry powder inhalers are reinforcing their dominance.

The aerosol liquid segment is anticipated to witness the fastest CAGR of 8.7% from 2026 to 2033, driven by its widespread use in metered-dose inhalers (MDIs). These inhalers are commonly used for quick relief and are highly effective in acute conditions. Technological advancements in propellant systems are improving safety and environmental sustainability. Increasing demand for fast-acting drug delivery systems is supporting growth. The segment is also benefiting from strong adoption in hospital and emergency care settings. Rising awareness regarding proper inhaler usage is further enhancing effectiveness. In addition, pharmaceutical companies are investing in improving inhaler design and functionality. The availability of affordable MDI devices is supporting adoption in developing regions. Growing patient preference for convenient and reliable treatment options is also contributing to growth. Overall, the segment is expected to expand steadily over the forecast period.

• By End-Users

On the basis of end-users, the market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment dominated the market with a revenue share of 39.8% in 2025, owing to the high patient inflow for respiratory diseases and access to advanced treatment facilities. Hospitals play a critical role in managing severe asthma and COPD cases, driving significant demand for inhaled corticosteroids. The presence of skilled healthcare professionals and advanced diagnostic tools further supports segment growth. Increasing hospital admissions due to respiratory complications are also contributing to demand. In addition, hospitals offer comprehensive care, including diagnosis, treatment, and follow-up services. Government investments in healthcare infrastructure are strengthening hospital capabilities. The rising prevalence of chronic respiratory diseases is further boosting segment growth. Moreover, hospitals are adopting advanced inhalation therapies to improve patient outcomes.

The homecare segment is expected to grow at the fastest CAGR of 10.2% from 2026 to 2033, driven by the increasing preference for home-based treatment. Patients are increasingly opting for self-administration of inhalers for long-term disease management. The availability of user-friendly inhalation devices is supporting this trend. In addition, rising healthcare costs are encouraging a shift toward homecare solutions. The growing elderly population and increasing chronic disease burden are further driving demand. Technological advancements in portable inhalers are enhancing convenience and adherence. Improved patient awareness and education are also supporting segment growth. Furthermore, healthcare providers are promoting home-based care to reduce hospital burden. The expansion of telehealth services is also contributing to segment development. Overall, the segment is expected to witness rapid growth in the coming years.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. The retail pharmacy segment dominated the market with a share of 46.1% in 2025, driven by its widespread accessibility and convenience. Patients prefer retail pharmacies due to easy availability of medications and pharmacist support. The segment benefits from a well-established distribution network across urban and rural areas. Continuous demand for chronic disease medications ensures steady growth. In addition, retail pharmacies provide immediate access to prescriptions, enhancing patient adherence. The increasing number of pharmacy outlets is further supporting segment expansion. Pharmaceutical companies are also strengthening partnerships with retail chains. The rising awareness regarding respiratory disease management is contributing to growth. Moreover, competitive pricing and availability of generic drugs are attracting more consumers.

The online pharmacy segment is projected to witness the fastest CAGR of 11.3% from 2026 to 2033, driven by rapid digitalization and growing e-commerce adoption. Patients are increasingly opting for online platforms due to convenience and home delivery services. The segment is benefiting from competitive pricing and discounts offered by online providers. Increased internet penetration and smartphone usage are supporting growth. The COVID-19 pandemic has accelerated the shift toward digital healthcare solutions. In addition, online pharmacies provide easy access to a wide range of medications. Improved logistics and supply chain systems are enhancing delivery efficiency. The integration of telemedicine services is also boosting demand. Rising consumer preference for contactless purchasing is further contributing to growth. Overall, the segment is expected to expand significantly over the forecast period.

Inhaled Corticosteroids Market Regional Analysis

• North America dominated the inhaled corticosteroids market with the largest revenue share of 36.8% in 2025, driven by the high prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), advanced healthcare infrastructure, and the strong presence of leading pharmaceutical companies
• The region benefits from widespread adoption of combination inhaler therapies, increasing awareness regarding respiratory disease management, and well-established reimbursement frameworks, particularly in the U.S., which further support market growth
• In addition, ongoing advancements in inhalation drug delivery technologies and increasing focus on improving patient adherence are contributing to sustained demand across both hospital and homecare settings

U.S. Inhaled Corticosteroids Market Insight

The U.S. inhaled corticosteroids market captured the largest revenue share within North America in 2025, fueled by the high burden of asthma and COPD, strong adoption of advanced inhalation therapies, and robust healthcare spending. The presence of major pharmaceutical players, continuous product innovations, and increasing preference for combination inhalers are key factors driving market growth. Furthermore, rising awareness regarding early diagnosis and long-term disease management continues to support the expansion of the market in the country.

Europe Inhaled Corticosteroids Market Insight

The Europe inhaled corticosteroids market is projected to expand at a substantial CAGR during the forecast period, primarily driven by increasing prevalence of respiratory disorders, strong regulatory support, and growing emphasis on preventive healthcare. The region’s well-established healthcare systems and rising adoption of advanced inhalation therapies are contributing to market growth. In addition, increasing awareness regarding disease management and adherence to treatment guidelines are further supporting demand.

U.K. Inhaled Corticosteroids Market Insight

The U.K. inhaled corticosteroids market is anticipated to grow at a noteworthy CAGR, driven by rising incidence of asthma and COPD, increasing healthcare awareness, and strong government initiatives focused on respiratory health. The country’s well-developed healthcare infrastructure and growing emphasis on early diagnosis and treatment are key factors supporting market expansion.

Germany Inhaled Corticosteroids Market Insight

The Germany inhaled corticosteroids market is expected to expand at a considerable CAGR, supported by advanced healthcare infrastructure, high healthcare expenditure, and strong focus on innovation in respiratory care. Increasing adoption of combination inhalers and growing awareness regarding chronic respiratory disease management are further contributing to market growth.

Asia-Pacific Inhaled Corticosteroids Market Insight

The Asia-Pacific inhaled corticosteroids market is expected to grow at the fastest CAGR during the forecast period, driven by rising pollution levels, increasing patient population, and improving healthcare access across emerging economies. Growing awareness regarding respiratory diseases, expanding healthcare infrastructure, and increasing adoption of advanced treatment options are key factors accelerating market growth in the region.

Japan Inhaled Corticosteroids Market Insight

The Japan inhaled corticosteroids market is gaining momentum due to the country’s aging population, increasing prevalence of respiratory diseases, and strong focus on advanced healthcare solutions. High adoption of innovative inhalation therapies and emphasis on long-term disease management are supporting market expansion.

China Inhaled Corticosteroids Market Insight

The China inhaled corticosteroids market accounted for the largest revenue share in Asia-Pacific in 2025, attributed to rising pollution levels, a large patient population, and rapid improvements in healthcare infrastructure. Increasing awareness regarding respiratory disease treatment, along with expanding access to affordable medications and growing pharmaceutical manufacturing capabilities, are key factors propelling the market in China.

Inhaled Corticosteroids Market Share

The Inhaled Corticosteroids industry is primarily led by well-established companies, including:

• GlaxoSmithKline plc (U.K.)
• AstraZeneca plc (U.K.)
• Teva Pharmaceutical Industries Ltd (Israel)
• Novartis AG (Switzerland)
• Boehringer Ingelheim International GmbH (Germany)
• Merck & Co., Inc. (U.S.)
• Sanofi S.A. (France)
• Cipla Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Lupin Limited (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Hikma Pharmaceuticals plc (U.K.)
• Chiesi Farmaceutici S.p.A. (Italy)
• Orion Corporation (Finland)
• Mylan N.V. (U.S.)
• Glenmark Pharmaceuticals Ltd. (India)
• Zydus Lifesciences Ltd. (India)
• Torrent Pharmaceuticals Ltd. (India)
• Viatris Inc. (U.S.)
• Mundipharma International Limited (U.K.)

Latest Developments in Global Inhaled Corticosteroids Market

• In February 2021, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) approved Airsupra (albuterol/budesonide), an inhaled corticosteroid and bronchodilator combination therapy, for the as-needed treatment of asthma in adults. This marked a significant advancement in combining rescue and anti-inflammatory therapy in a single inhaler
• In July 2022, Glenmark Pharmaceuticals launched a generic version of Budesonide Inhalation Suspension in the U.S., following FDA approval, providing a cost-effective alternative for asthma management. This launch strengthened access to inhaled corticosteroid therapies through generic competition
• In April 2023, Chiesi Farmaceutici announced the U.S. FDA approval of Airsupra (albuterol/budesonide), the first as-needed combination inhaler for asthma that includes an inhaled corticosteroid, aimed at reducing severe exacerbations. This approval highlighted innovation in combination inhaled therapies
• In May 2023, Cipla received approval from the U.S. FDA for its generic version of Fluticasone Propionate Metered Dose Inhaler, expanding its respiratory portfolio and increasing affordability of inhaled corticosteroids in key markets
• In January 2024, Teva Pharmaceuticals announced positive clinical trial results for its inhaled corticosteroid-based combination therapy for asthma, reinforcing its pipeline strength in respiratory treatments
• In March 2025, ongoing advancements in inhaled corticosteroid formulations, including digitally enabled inhalers and improved drug delivery technologies, were highlighted by industry leaders, emphasizing better patient adherence and treatment outcomes in asthma and COPD management

SKU-53925